BioventixFRA:51B -1.13%64 Days Payable is 368.42 as of Dec. 2025, which is 996% above its 10-year median of 33.62. GuruFocus rates FRA:51B with a GF Score™ of 64/100 and a GF Value™ of €38.68 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 700 Biotechnology companies, Bioventix ranks better than 79.14% on this metric.
Bioventix's average Accounts Payable for the
six
months ended in Dec. 2025 was €1.19 Mil. Bioventix's Cost of Goods Sold for the
six
months ended in Dec. 2025 was €0.59 Mil.
Hence, Bioventix's Days Payable for the
six
months ended in Dec. 2025 was 368.42.
The historical rank and industry rank for Bioventix's Days Payable or its related term are showing as below:
FRA:51B'
s Days Payable Range Over the Past 10 Years
Min: 9.59 Med: 33.62 Max: 487.44
Current: 487.44
During the past 13 years, Bioventix's highest Days Payable was 487.44. The lowest was 9.59. And the median was 33.62.
FRA:51B's Days Payable is ranked better than 79.14% of 700
companies
in the Biotechnology industry
Industry Median: 112.83
vs FRA:51B: 487.44
Bioventix's Days Payable
increased
from Dec. 2024 (226.49) to Dec. 2025 (368.42).
It may suggest that Bioventixdelayed paying its suppliers.
Bioventix Days Payable Related Terms
Bioventix Days Payable Historical Data
* Premium members only.
The historical data trend for Bioventix's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:51B vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Bioventix's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioventix Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bioventix's Days Payable distribution charts can be found below:
* The bar in red indicates where Bioventix's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Bioventix's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioventix (FRA:51B) has a Days Payable of 368.42 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bioventix and its competitors. This is 996% above median its historical median of 33.62. Over the past decade, Bioventix's Days Payable has ranged from 9.59 to 487.44. According to the industry distribution chart, Bioventix ranks #146 out of 700 companies in the Biotechnology industry, placing it in the top 20.9%.
Is Bioventix's Days Payable too high?
Bioventix's current Days Payable of 368.42 is 996% above median its 10-year median of 33.62. Over the past 10 years, this metric has ranged from a low of 9.59 to a high of 487.44. The Biotechnology industry median Days Payable is 112.83. Bioventix's value of 368.42 is 226.5% above this industry median. Based on the distribution chart, Bioventix ranks #146 out of 700 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bioventix has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioventix's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bioventix ranks #146 out of 700 companies for Days Payable. This places Bioventix in the top 21% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.83. Bioventix's value of 368.42 is 226.5% above this benchmark. Historically, Bioventix's own Days Payable has ranged from 9.59 to 487.44 over the past decade. While the company's 10-year median is 33.62 vs. the industry median of 112.83, Bioventix has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.83, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioventix's current Days Payable of 368.42 is 226.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bioventix and its competitors. For the Biotechnology industry, the median Days Payable is 112.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioventix's current Days Payable is 368.42, which is 996% above median its own 10-year median of 33.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioventix stock overvalued right now?
Based on GuruFocus' analysis, Bioventix (FRA:51B) is currently considered Significantly Undervalued. The stock's GF Value™ is €38.68, compared to a current price of €17.50 — trading 54.8% below its estimated fair value. The current Days Payable is 368.42, which is 996% above median its 10-year median of 33.62 and 226.5% above the Biotechnology industry median of 112.83. Bioventix's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Bioventix (FRA:51B), the current Days Payable is 368.42 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioventix (FRA:51B) Overvalued in 2026?
Based on GuruFocus' analysis, Bioventix stock appears to be undervalued.
The current stock price of €17.50 is trading 54.8% below its estimated GF Value™ of €38.68.
GuruFocus considers Bioventix to be Significantly Undervalued.
Key valuation signals for FRA:51B:
Days Payable: 368.42 (996% above median its 10-year median of 33.62)
GF Value™: €38.68 vs. price of €17.50 (54.8% below fair value)
Industry Position: 226.5% above the Biotechnology median (#146 of 700)
No single metric tells the full story. See the FRA:51B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
64GF Score
Get the complete analysis for FRA:51B
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:51B has been successfully added to your 
